Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design
Lawn, S.D.; Myer, L.; Orrell, C.; Bekker, L-Gail.; Wood, R.
Aids 19(18): 2141-2148
2005
ISSN/ISBN: 0269-9370 PMID: 16284464 Document Number: 259156
Objectives: To determine rates, risk factors and causes of death among patients accessing a community-based antiretroviral treatment (ART) programme both prior to and following initiation of treatment.Methods: All in-programme deaths were ascertained between September 2002 and March 2005 among treatment-naive patients enrolled into a prospective community-based ART cohort in Cape Town, South Africa.Results: Of 712 patients (median CD4 cell count, 94 cells/mu l), 578 (81 %) started triple ART a median of 29 days after enrolment. 68 (9.5%) patients died during 563 person-years of observation. The high pretreatment mortality rate of 35.6 deaths/100 person-years [95% confidence interval (0), 23.0-55.1) decreased to 2.5/100 person-years (95% Cl, 0.9-6.6) at 1 year among those who received ART. However, within the first 90 days from enrolment, 29 of 44 (66%) deaths occurred among patients awaiting ART; these would not be identified by an on-treatment analysis. Multivariate analysis showed that risk of death (both pre-treatment and on-treatment) was independently associated with baseline CD4 cell count and World Health Organization (WHO) clinical stage; stage 4 disease was the strongest risk factor. Major attributed causes of death were wasting syndrome, tuberculosis, acute bacterial infections, malignancy and immune reconstitution disease.Conclusions: Most early in-programme deaths occurred among patients with advanced immunodeficiency but who had not yet started ART. Programme evaluation using ontreatment analyses greatly underestimated early mortality. This mortality would be reduced by minimizing unnecessary in-programme delays in treatment initiation and by starting ART before development of WHO stage 4 disease. (c) 2005 Lippincott Williams & Wilkins.